Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Randomized Trial Comparing Robotic and Open Radical Cystectomy

Phase 3

Completed

Conditions: Bladder Cancer

Interventions: Procedure: open radical cystectomy
Procedure: robotic-assisted radical cystectomy

First Posted Date: 2010-02-26

Last Posted Date: 2020-03-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 124

Registration Number: NCT01076387

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Vitamin D Levels in Stage IV Colorectal Cancer Patients

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)

First Posted Date: 2010-02-24

Last Posted Date: 2016-02-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT01074216

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States

and more 2 locations

Lung Cancer Exercise Training Study

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Behavioral: Exercise Training
Behavioral: Progressive Stretching

First Posted Date: 2010-02-12

Last Posted Date: 2024-04-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT01068210

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection

Not Applicable

Completed

Conditions: Pancreatic Cancer

Interventions: Other: restrictive perioperative fluid management
Other: Liberal perioperative fluid management

First Posted Date: 2010-01-29

Last Posted Date: 2019-09-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 331

Registration Number: NCT01058746

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

Not Applicable

Terminated

Conditions: Lung Cancer
Non-small Cell Lung Cancer

Interventions: Procedure: PET/CT and BH PET/CT

First Posted Date: 2010-01-20

Last Posted Date: 2012-03-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT01052766

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Phase 1

Completed

Conditions: Pediatric Solid Tumors

Interventions: Drug: perifosine + temsirolimus

First Posted Date: 2010-01-15

Last Posted Date: 2017-03-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT01049841

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Leukemia

Interventions: Biological: gene-modified T cells targeted

First Posted Date: 2010-01-07

Last Posted Date: 2024-02-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 93

Registration Number: NCT01044069

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Phase 2

Completed

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: everolimus

First Posted Date: 2009-12-03

Last Posted Date: 2015-05-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT01024946

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Phase 2

Completed

Conditions: Thyroid Cancer

Interventions: Drug: Temsirolimus and Sorafenib

First Posted Date: 2009-12-03

Last Posted Date: 2018-08-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 37

Registration Number: NCT01025453

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States

and more 2 locations

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

Phase 2

Active, not recruiting

Conditions: Thymoma
Clinical Masaoka Stage II to IVA
Thymic Carcinoma

Interventions: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide

First Posted Date: 2009-12-03

Last Posted Date: 2025-01-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT01025089

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy